Introduction:
Univercells Technologies has announced an expansion of its partnership with the Gene Therapy Program at the University of Pennsylvania (GTP). The partnership aims to evaluate the scalability of GTP’s gene therapy product manufacturing using Univercells Technologies’ bioreactors.
- The Gene Therapy Program at the University of Pennsylvania (GTP) is expanding its evaluation agreement with Univercells Technologies to determine the scalability of gene therapy product manufacturing.
- GTP, led by James M. Wilson, focuses on genetic medicines and aims to make gene therapies for rare diseases accessible worldwide.
- The evaluation agreement covers GTP’s assessment of Univercells Technologies’ commercial-series scale-X™ nitro 600 m2 bioreactor, with the goal of increasing production and reducing costs.
- Univercells Technologies developed the scale-X bioreactor with the support of the Bill and Melinda Gates Foundation, and it is now being used to enable viral vector accessibility for gene therapies.
- The partnership between GTP and Univercells Technologies aligns with the mission of making gene therapies more accessible globally through innovative bioprocessing technologies.
Conclusion:
The expansion of the partnership between Univercells Technologies and the University of Pennsylvania’s Gene Therapy Program highlights the importance of scaling up gene therapy manufacturing and reducing costs to make rare disease treatments more accessible worldwide. Univercells Technologies’ innovative bioreactors offer the potential to increase production and improve efficiency, contributing to the mission of making gene therapies more affordable and accessible in the future.
